血液筛查ELISA方法检测抗-HCV设置灰区的必要性探讨

陈善华, 朱丽莉, 吕素梅. 血液筛查ELISA方法检测抗-HCV设置灰区的必要性探讨[J]. 临床血液学杂志, 2019, 32(10): 807-809. doi: 10.13201/j.issn.1004-2806-b.2019.10.022
引用本文: 陈善华, 朱丽莉, 吕素梅. 血液筛查ELISA方法检测抗-HCV设置灰区的必要性探讨[J]. 临床血液学杂志, 2019, 32(10): 807-809. doi: 10.13201/j.issn.1004-2806-b.2019.10.022
CHEN Shanhua, ZHU Lili, LV Sumei. Discussion on the necessity of detecting Anti-HCV setting gray area by blood screening ELISA method[J]. J Clin Hematol, 2019, 32(10): 807-809. doi: 10.13201/j.issn.1004-2806-b.2019.10.022
Citation: CHEN Shanhua, ZHU Lili, LV Sumei. Discussion on the necessity of detecting Anti-HCV setting gray area by blood screening ELISA method[J]. J Clin Hematol, 2019, 32(10): 807-809. doi: 10.13201/j.issn.1004-2806-b.2019.10.022

血液筛查ELISA方法检测抗-HCV设置灰区的必要性探讨

详细信息
    通讯作者: 陈善华,E-mail:1521728943@qq.com
  • 中图分类号: R457.1

Discussion on the necessity of detecting Anti-HCV setting gray area by blood screening ELISA method

More Information
  • 加载中
  • [1]

    Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5:558-567.

    [2]

    Xia R,Lu L,Wang J,et al.Correlation of viral loads with HCV genotypes:higher levels of virus were revealed among blood donors infected with 6 strains[J].PLos One,2012,7:452-467.

    [3]

    Mohd HK,Groeger J,Flaxman AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57:1333-1342.

    [4]

    钟江,陈文霞,刘玉娇,等.无偿献血者抗-HCV筛查与RIBA补充实验情况的综合分析[J].中国输血杂志,2016,29(6):616-619.

    [5]

    李育芬,楚承霞,杨颖.HCV检测方法研究进展及其临床意义[J].中国卫生检验杂志,2013,23(5):1342-1344.

    [6]

    陈菲,骆珊,郭风繁,等.丙型肝炎病毒各感染状态外周血中白细胞介素8表达水平研究[J].现代医院,2016,16(2):164-166.

    [7]

    任宪辉,姚冬杰,张洋.丙型肝炎患者HCV-RNA感染与血清自身抗体的相关性分析[J].国外医学(医学地理分册),2016,37(2):131-133.

    [8]

    Costantino A,Spada E,Equestre M,et al.Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-nave patients with chronic hepatitis C[J].Virol J,2015,12:186.

    [9]

    Walker DR,Pedrosa MC,Manthena SR,et al.Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)[J].Adv Ther,2015,32:1117-1127.

    [10]

    卢香云,程江,包建玲,等.ELISA法检测丙型肝炎病毒抗体最佳临界值及其可疑区间[J].现代预防医学,2015,42(10):1841-1844.

    [11]

    彭吉芳.丙型肝炎病毒检测假阳性1例[J].临床输血与检验,2014,16(2):217-218.

    [12]

    李金明.感染性疾病血清学检验中应重视对弱反应性标本的确认[J].中华检验医学杂志,2006,29(7):577-580.

  • 加载中
    Created with Highcharts 5.0.7访问量Chart context menu近一年内文章摘要浏览量、PDF下载量统计信息摘要浏览量PDF下载量2024-072024-082024-092024-102024-112024-122025-012025-022025-032025-042025-052025-0601234Highcharts.com
    Created with Highcharts 5.0.7Chart context menu访问类别分布HTML全文: 100.0 %HTML全文: 100.0 %HTML全文Highcharts.com
    Created with Highcharts 5.0.7Chart context menu访问地区分布其他: 11.8 %其他: 11.8 %伊利诺伊州: 1.2 %伊利诺伊州: 1.2 %北京: 1.2 %北京: 1.2 %十堰: 2.4 %十堰: 2.4 %嘉兴: 1.2 %嘉兴: 1.2 %天津: 4.7 %天津: 4.7 %宣城: 1.2 %宣城: 1.2 %常州: 2.4 %常州: 2.4 %张家口: 11.8 %张家口: 11.8 %扬州: 2.4 %扬州: 2.4 %杭州: 1.2 %杭州: 1.2 %格兰特县: 1.2 %格兰特县: 1.2 %武汉: 1.2 %武汉: 1.2 %温州: 1.2 %温州: 1.2 %漯河: 3.5 %漯河: 3.5 %石家庄: 4.7 %石家庄: 4.7 %芒廷维尤: 31.8 %芒廷维尤: 31.8 %芝加哥: 9.4 %芝加哥: 9.4 %衡阳: 1.2 %衡阳: 1.2 %西宁: 2.4 %西宁: 2.4 %贵阳: 1.2 %贵阳: 1.2 %马鞍山: 1.2 %马鞍山: 1.2 %其他伊利诺伊州北京十堰嘉兴天津宣城常州张家口扬州杭州格兰特县武汉温州漯河石家庄芒廷维尤芝加哥衡阳西宁贵阳马鞍山Highcharts.com
计量
  • 文章访问数:  306
  • PDF下载数:  911
  • 施引文献:  0
出版历程
收稿日期:  2019-03-08

目录